Surrogate markers of transplant vasculopathy

Mohamad H. Yamani; Randall C. Starling

doi:10.1097/01.mot.0000146564.50774.82

Surrogate markers of transplant vasculopathy

Mohamad H. Yamani, Randall C. Starling

Cardiovascular Diseases

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

The clinical utility of these markers will have to be confirmed and validated in large clinical trials before they are accepted as surrogate markers for the development of vasculopathy.

Original language	English (US)
Pages (from-to)	443-447
Number of pages	5
Journal	Current opinion in organ transplantation
Volume	9
Issue number	4
DOIs	https://doi.org/10.1097/01.mot.0000146564.50774.82
State	Published - Dec 2004

Keywords

Heart transplantation
Surrogate
Transplant vasculopathy

ASJC Scopus subject areas

Immunology and Allergy
Transplantation

Access to Document

10.1097/01.mot.0000146564.50774.82

Cite this

@article{9b58e32284774a8a9b1a3bde0ce7a6cd,

title = "Surrogate markers of transplant vasculopathy",

abstract = "The clinical utility of these markers will have to be confirmed and validated in large clinical trials before they are accepted as surrogate markers for the development of vasculopathy.",

keywords = "Heart transplantation, Surrogate, Transplant vasculopathy",

author = "Yamani, {Mohamad H.} and Starling, {Randall C.}",

year = "2004",

month = dec,

doi = "10.1097/01.mot.0000146564.50774.82",

language = "English (US)",

volume = "9",

pages = "443--447",

journal = "Current opinion in organ transplantation",

issn = "1087-2418",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Surrogate markers of transplant vasculopathy

AU - Yamani, Mohamad H.

AU - Starling, Randall C.

PY - 2004/12

Y1 - 2004/12

N2 - The clinical utility of these markers will have to be confirmed and validated in large clinical trials before they are accepted as surrogate markers for the development of vasculopathy.

AB - The clinical utility of these markers will have to be confirmed and validated in large clinical trials before they are accepted as surrogate markers for the development of vasculopathy.

KW - Heart transplantation

KW - Surrogate

KW - Transplant vasculopathy

UR - http://www.scopus.com/inward/record.url?scp=16344365623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344365623&partnerID=8YFLogxK

U2 - 10.1097/01.mot.0000146564.50774.82

DO - 10.1097/01.mot.0000146564.50774.82

M3 - Review article

AN - SCOPUS:16344365623

SN - 1087-2418

VL - 9

SP - 443

EP - 447

JO - Current opinion in organ transplantation

JF - Current opinion in organ transplantation

IS - 4

ER -

Surrogate markers of transplant vasculopathy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this